Glück Conviction Score™ ⓘ
VRTX
VERTEX PHARMACEUTICALS INC / MA
ⓘ
Eingeschränkte Aussagekraft — erst 64 % der Signal-Gewichte sind mit Daten unterlegt.
Effektiv: Neutral
Sehr hoch
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
45,0
144 neu, 671 erhöht, -6056145K $ netto
Aktivist
27,0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 436.75 | +1.9 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 438.43 | +1.5 % vs SMA200 | |
| SMA-Cross | Bärisch | 10 % | DEATH | vor 5 Tagen @ 446.83 | |
| EMA20 vs EMA50 | Bärisch | 5 % | 439.71 | EMA50: 440.98 | |
| MACD-Histogramm | Bullisch | 10 % | 0.804 | Bullisch | |
| RSI(14) | Neutral | 10 % | 53.8 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 75.2 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 12.2 | +DI: 21.1 / −DI: 21.8 | |
| Z-Score(60) | Neutral | 5 % | 0.70 | In Range | |
| 52W-Position | Neutral | 5 % | 59.1 % | Hoch 499.17 / Tief 366.54 | |
| Bollinger(20,2σ) | Neutral | 5 % | 74.9 % | Upper 451.42 / Mid 438.49 / Lower 425.56 | |
| LinReg-Slope(60) | Neutral | 10 % | -0.1285 | R²=0.06 / annualisiert -7.4 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-06-05 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -1.745 | 450,00 | -785.250,00 | -45,7% | |
| 2026-06-01 | Liu Joy | Officer, EVP and Chief Legal Officer | Open Market Sale | -828 | 439,91 | -364.245,48 | -21,2% | |
| 2026-05-29 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -1.974 | 450,00 | -888.300,00 | -51,7% | |
| 2026-05-15 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -1.354 | 453,45 | -613.971,30 | -35,7% | |
| 2026-05-15 | Bunnage Mark E. | Officer, EVP, Chief Scientific Officer | Open Market Sale | -33 | 453,45 | -14.963,85 | -0,9% | |
| 2026-05-12 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -6.988 | 450,00 | -3.144.600,00 | -183,1% | |
| 2026-05-04 | Bhatia Sangeeta N. | Director | Open Market Sale | -318 | 423,73 | -134.746,14 | -7,8% | |
| 2026-05-01 | Liu Joy | Officer, EVP and Chief Legal Officer | Open Market Sale | -1.104 | 425,02 | -469.222,08 | -27,3% | |
| 2026-04-01 | Liu Joy | Officer, EVP and Chief Legal Officer | Open Market Sale | -978 | 449,17 | -439.288,26 | -25,6% | |
| 2026-03-27 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -2.329 | 450,95 | -1.050.262,55 | -61,1% | |
| 2026-03-13 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -2.329 | 481,79 | -1.122.088,91 | -65,3% | |
| 2026-03-11 | McKechnie Duncan | Officer, EVP, Chief Commercial Officer | Open Market Sale | -2.633 | 498,42 | -1.312.339,86 | -76,4% | |
| 2026-03-04 | McKechnie Duncan | Officer, EVP, Chief Commercial Officer | Open Market Sale | -2.437 | 475,30 | -1.158.306,10 | -67,4% | |
| 2026-03-02 | Liu Joy | Officer, EVP and Chief Legal Officer | Open Market Sale | -892 | 495,96 | -442.396,32 | -25,8% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -3.278 | 488,27 | -1.600.549,06 | -93,2% | |
| 2026-02-27 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -2.329 | 480,31 | -1.118.641,99 | -65,1% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -15.580 | 495,38 | -7.718.020,40 | -449,4% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -5.995 | 496,16 | -2.974.479,20 | -173,2% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -3.498 | 494,33 | -1.729.166,34 | -100,7% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -2.725 | 490,54 | -1.336.721,50 | -77,8% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -2.520 | 493,29 | -1.243.090,80 | -72,4% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -2.510 | 487,13 | -1.222.696,30 | -71,2% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -1.725 | 496,95 | -857.238,75 | -49,9% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -949 | 491,30 | -466.243,70 | -27,1% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -460 | 489,32 | -225.087,20 | -13,1% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -400 | 479,75 | -191.900,00 | -11,2% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -240 | 482,84 | -115.881,60 | -6,7% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -120 | 481,50 | -57.780,00 | -3,4% | |
| 2026-02-26 | Ambrose Kristen | Officer, SVP & Chief Accounting Officer | Open Market Sale | -357 | 483,36 | -172.559,52 | -10,0% | |
| 2026-02-25 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -260 | 486,35 | -126.451,00 | -7,4% | |
| 2026-02-25 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -1.846 | 486,35 | -897.802,10 | -52,3% | |
| 2026-02-25 | Atkinson Edward Morrow III | Officer, EVP, Chief Technical Ops. Off. | Open Market Sale | -668 | 486,35 | -324.881,80 | -18,9% | |
| 2026-02-25 | Ambrose Kristen | Officer, SVP & Chief Accounting Officer | Open Market Sale | -223 | 486,35 | -108.456,05 | -6,3% | |
| 2026-02-25 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -945 | 486,35 | -459.600,75 | -26,8% | |
| 2026-02-25 | Bunnage Mark E. | Officer, EVP, Chief Scientific Officer | Open Market Sale | -620 | 486,35 | -301.537,00 | -17,6% | |
| 2026-02-25 | McKechnie Duncan | Officer, EVP, Chief Commercial Officer | Open Market Sale | -2.410 | 489,00 | -1.178.490,00 | -68,6% | |
| 2026-02-25 | McKechnie Duncan | Officer, EVP, Chief Commercial Officer | Open Market Sale | -2.500 | 486,35 | -1.215.875,00 | -70,8% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -1.848 | 465,80 | -860.798,40 | -50,1% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -11.712 | 470,54 | -5.510.964,48 | -320,9% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -2.730 | 465,05 | -1.269.586,50 | -73,9% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -7.241 | 469,61 | -3.400.446,01 | -198,0% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -4.237 | 471,43 | -1.997.448,91 | -116,3% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -19.662 | 468,57 | -9.213.023,34 | -536,4% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -920 | 463,91 | -426.797,20 | -24,8% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -10.263 | 467,75 | -4.800.518,25 | -279,5% | |
| 2026-02-18 | Bunnage Mark E. | Officer, EVP, Chief Scientific Officer | Open Market Sale | -1.182 | 473,68 | -559.889,76 | -32,6% | |
| 2026-02-18 | Ambrose Kristen | Officer, SVP & Chief Accounting Officer | Open Market Sale | -638 | 473,68 | -302.207,84 | -17,6% | |
| 2026-02-18 | Atkinson Edward Morrow III | Officer, EVP, Chief Technical Ops. Off. | Open Market Sale | -817 | 473,68 | -386.996,56 | -22,5% | |
| 2026-02-18 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -1.244 | 473,68 | -589.257,92 | -34,3% | |
| 2026-02-18 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -368 | 473,68 | -174.314,24 | -10,1% | |
| 2026-02-17 | Atkinson Edward Morrow III | Officer, EVP, Chief Technical Ops. Off. | Open Market Sale | -2.031 | 489,46 | -994.093,26 | -57,9% | |
| 2026-02-17 | Bunnage Mark E. | Officer, EVP, Chief Scientific Officer | Open Market Sale | -2.437 | 489,46 | -1.192.814,02 | -69,4% | |
| 2026-02-17 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -2.476 | 489,46 | -1.211.902,96 | -70,6% | |
| 2026-02-17 | Ambrose Kristen | Officer, SVP & Chief Accounting Officer | Open Market Sale | -1.557 | 489,46 | -762.089,22 | -44,4% | |
| 2026-02-17 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -609 | 489,46 | -298.081,14 | -17,4% | |
| 2026-02-13 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -988 | 499,00 | -493.012,00 | -28,7% | |
| 2026-02-13 | Bhatia Sangeeta N. | Director | Open Market Sale | -266 | 500,00 | -133.000,00 | -7,7% | |
| 2026-02-13 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -1.500 | 499,99 | -749.985,00 | -43,7% | |
| 2026-02-11 | Ambrose Kristen | Officer, SVP & Chief Accounting Officer | Open Market Sale | -1.376 | 460,43 | -633.551,68 | -36,9% | |
| 2026-02-11 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -1.925 | 460,43 | -886.327,75 | -51,6% | |
| 2026-02-11 | Bunnage Mark E. | Officer, EVP, Chief Scientific Officer | Open Market Sale | -2.021 | 460,43 | -930.529,03 | -54,2% | |
| 2026-02-11 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -466 | 460,43 | -214.560,38 | -12,5% | |
| 2026-02-11 | Atkinson Edward Morrow III | Officer, EVP, Chief Technical Ops. Off. | Open Market Sale | -1.751 | 460,43 | -806.212,93 | -46,9% | |
| 2026-01-07 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -4.500 | 474,99 | -2.137.455,00 | -124,4% | |
| 2026-01-06 | WAGNER CHARLES F JR | Officer, EVP, CO & FO | Open Market Sale | -9.532 | 461,00 | -4.394.252,00 | -255,8% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -4.352 | 444,36 | -1.933.854,72 | -112,6% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -2.469 | 443,21 | -1.094.285,49 | -63,7% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -2.320 | 448,78 | -1.041.169,60 | -60,6% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -2.070 | 455,22 | -942.305,40 | -54,9% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -1.320 | 441,26 | -582.463,20 | -33,9% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -1.152 | 447,05 | -515.001,60 | -30,0% | |
| 2025-12-03 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -347 | 449,00 | -155.803,00 | -9,1% | |
| 2025-12-03 | WAGNER CHARLES F JR | Officer, EVP, CO & FO | Open Market Sale | -7.000 | 461,00 | -3.227.000,00 | -187,9% | |
| 2025-12-03 | WAGNER CHARLES F JR | Officer, EVP, CO & FO | Open Market Sale | -7.000 | 451,00 | -3.157.000,00 | -183,8% | |
| 2025-12-03 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -4.500 | 449,99 | -2.024.955,00 | -117,9% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -15.681 | 452,20 | -7.090.948,20 | -412,8% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -10.360 | 453,34 | -4.696.602,40 | -273,4% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -7.899 | 445,56 | -3.519.478,44 | -204,9% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -5.880 | 449,84 | -2.645.059,20 | -154,0% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -5.809 | 451,20 | -2.621.020,80 | -152,6% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -4.469 | 440,40 | -1.968.147,60 | -114,6% | |
| 2025-11-17 | Atkinson Edward Morrow III | Officer, EVP, Chief Technical Ops. Off. | Open Market Sale | -2.500 | 434,58 | -1.086.450,00 | -63,3% | |
| 2025-11-14 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -21.330 | 441,35 | -9.413.995,50 | -548,1% | |
| 2025-11-14 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -32.234 | 440,30 | -14.192.630,20 | -826,3% | |
| 2025-11-14 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -40 | 442,00 | -17.680,00 | -1,0% | |
| 2025-11-13 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -18.528 | 440,22 | -8.156.396,16 | -474,9% | |
| 2025-11-13 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -1.160 | 441,05 | -511.618,00 | -29,8% | |
| 2025-10-02 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -694 | 404,21 | -280.521,74 | -16,3% | |
| 2025-08-27 | Bhatia Sangeeta N. | Director | Open Market Sale | -266 | 386,69 | -102.859,54 | -6,0% | |
| 2025-08-06 | SACHS BRUCE I | Director | Open Market Purchase | 3.366 | 389,84 | 1.312.201,44 | +76,4% | |
| 2025-08-06 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Purchase | 5.710 | 389,95 | 2.226.614,50 | +129,6% | |
| 2025-08-06 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Purchase | 4.290 | 389,08 | 1.669.153,20 | +97,2% | |
| 2025-08-06 | SACHS BRUCE I | Director | Open Market Purchase | 1.634 | 389,36 | 636.214,24 | +37,0% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| Capital World Investors | 25.368.124 | 25.510.182 | -142.058 | 11.327.759.436 | Reduziert | -0,6% | |
| VANGUARD GROUP INC | 24.105.823 | 0 | 24.105.823 | 10.928.615.915 | Neu | +100,0% | |
| BlackRock, Inc. | 23.969.517 | 23.751.989 | 217.528 | 10.703.348.322 | Aufgestockt | +0,9% | |
| Capital Research Global Investors | 21.125.964 | 17.316.344 | 3.809.620 | 9.433.408.963 | Aufgestockt | +22,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 16.512.810 | 0 | 16.512.810 | 7.373.630.177 | Neu | +100,0% | |
| STATE STREET CORP | 11.730.139 | 11.689.539 | 40.600 | 5.237.976.269 | Aufgestockt | +0,3% | |
| JPMORGAN CHASE & CO | 6.039.481 | 0 | 6.039.481 | 2.738.059.237 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 6.139.621 | 5.981.905 | 157.716 | 2.730.054.399 | Aufgestockt | +2,6% | |
| Capital International Investors | 5.126.077 | 4.733.596 | 392.481 | 2.288.942.362 | Aufgestockt | +8,3% | |
| LOOMIS SAYLES & CO L P | 4.003.821 | 4.033.525 | -29.704 | 1.787.866.287 | Reduziert | -0,7% | |
| ALLIANCEBERNSTEIN L.P. | 3.910.786 | 4.496.482 | -585.696 | 1.772.993.941 | Reduziert | -13,0% | |
| NORGES BANK | 3.176.613 | 0 | 3.176.613 | 1.440.149.270 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 3.212.589 | 3.821.731 | -609.142 | 1.434.549.493 | Reduziert | -15,9% | |
| MORGAN STANLEY | 3.188.881 | 3.120.310 | 68.571 | 1.423.964.743 | Aufgestockt | +2,2% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 3.057.396 | 3.000.778 | 56.618 | 1.365.249.611 | Aufgestockt | +1,9% | |
| BANK OF AMERICA CORP /DE/ | 2.878.183 | 2.937.030 | -58.847 | 1.285.223.702 | Reduziert | -2,0% | |
| JENNISON ASSOCIATES LLC | 2.740.059 | 3.249.541 | -509.482 | 1.223.546.148 | Reduziert | -15,7% | |
| Clearbridge Investments, LLC | 2.700.975 | 2.860.176 | -159.201 | 1.206.093.269 | Reduziert | -5,6% | |
| AMERIPRISE FINANCIAL INC | 2.633.481 | 2.263.732 | 369.749 | 1.175.957.388 | Aufgestockt | +16,3% | |
| NORTHERN TRUST CORP | 2.564.264 | 2.579.457 | -15.193 | 1.145.046.448 | Reduziert | -0,6% | |
| Invesco Ltd. | 2.561.057 | 2.152.672 | 408.385 | 1.143.614.420 | Aufgestockt | +19,0% | |
| GOLDMAN SACHS GROUP INC | 2.466.575 | 1.812.218 | 654.357 | 1.101.424.226 | Aufgestockt | +36,1% | |
| JANUS HENDERSON GROUP PLC | 2.131.527 | 2.221.953 | -90.426 | 951.794.666 | Reduziert | -4,1% | |
| FMR LLC | 2.020.265 | 2.212.596 | -192.331 | 902.128.614 | Reduziert | -8,7% | |
| Legal & General Group Plc | 1.955.764 | 1.970.105 | -14.341 | 873.326.855 | Reduziert | -0,7% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.920.871 | 1.859.221 | 61.650 | 857.745.736 | Aufgestockt | +3,3% | |
| VICTORY CAPITAL MANAGEMENT INC | 1.888.521 | 3.356.766 | -1.468.245 | 843.328.237 | Reduziert | -43,7% | |
| DEUTSCHE BANK AG\ | 1.537.736 | 1.768.881 | -231.145 | 686.660.634 | Reduziert | -13,1% | |
| Amundi | 1.472.496 | 1.304.161 | 168.335 | 657.528.364 | Aufgestockt | +12,9% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.283.721 | 1.157.996 | 125.725 | 573.232.775 | Aufgestockt | +10,9% | |
| WCM INVESTMENT MANAGEMENT, LLC | 1.121.341 | 1.129.145 | -7.804 | 496.933.478 | Reduziert | -0,7% | |
| ROYAL BANK OF CANADA | 1.111.871 | 1.294.512 | -182.641 | 496.496.000 | Reduziert | -14,1% | |
| Nuveen, LLC | 1.084.495 | 1.042.397 | 42.098 | 484.270.397 | Aufgestockt | +4,0% | |
| DIMENSIONAL FUND ADVISORS LP | 989.342 | 945.660 | 43.682 | 441.758.953 | Aufgestockt | +4,6% | |
| Winslow Capital Management, LLC | 887.640 | 0 | 887.640 | 405.097.722 | Neu | +100,0% | |
| EDGEWOOD MANAGEMENT LLC | 905.129 | 1.060.075 | -154.946 | 404.176.304 | Reduziert | -14,6% | |
| BNP Paribas Asset Management Holding S.A. | 848.047 | 669.807 | 178.240 | 378.713.334 | Aufgestockt | +26,6% | |
| AMERICAN CENTURY COMPANIES INC | 813.285 | 848.639 | -35.354 | 363.164.284 | Reduziert | -4,2% | |
| WELLS FARGO & COMPANY/MN | 744.995 | 755.413 | -10.418 | 332.669.307 | Reduziert | -1,4% | |
| Swiss National Bank | 744.600 | 702.600 | 42.000 | 332.493.684 | Aufgestockt | +6,0% | |
| UBS Group AG | 742.718 | 651.082 | 91.636 | 331.653.296 | Aufgestockt | +14,1% | |
| CITIGROUP INC | 733.107 | 586.730 | 146.377 | 327.361.510 | Aufgestockt | +24,9% | |
| BARCLAYS PLC | 684.963 | 851.758 | -166.795 | 305.863.378 | Reduziert | -19,6% | |
| Bellevue Group AG | 681.908 | 681.120 | 788 | 304.499.199 | Aufgestockt | +0,1% | |
| HSBC HOLDINGS PLC | 667.943 | 658.289 | 9.654 | 298.242.420 | Aufgestockt | +1,5% | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 638.950 | 593.947 | 45.003 | 285.316.733 | Aufgestockt | +7,6% | |
| CITADEL ADVISORS LLC | 631.498 | 789.960 | -158.462 | 281.989.117 | Reduziert | -20,1% | |
| Sumitomo Mitsui Trust Group, Inc. | 614.448 | 654.470 | -40.022 | 274.375.610 | Reduziert | -6,1% | |
| Mitsubishi UFJ Asset Management Co., Ltd. | 597.497 | 566.227 | 31.270 | 266.806.310 | Aufgestockt | +5,5% | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 553.243 | 557.713 | -4.470 | 247.045.129 | Reduziert | -0,8% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| Capital World Investors | 25.368.124 | 25.510.182 | -0,6% | 11.327.759.436 | 11,52 |
| BlackRock, Inc. | 23.969.517 | 23.751.989 | +0,9% | 10.703.348.322 | 10,89 |
| Capital Research Global Investors | 21.125.964 | 17.316.344 | +22,0% | 9.433.408.963 | 9,59 |
| VANGUARD CAPITAL MANAGEMENT LLC | 16.512.810 | 0 | +100,0% | 7.373.630.177 | 7,50 |
| STATE STREET CORP | 11.730.139 | 11.689.539 | +0,3% | 5.237.976.269 | 5,33 |
| JPMORGAN CHASE & CO | 7.033.156 | 6.039.481 | +16,5% | 3.116.813.989 | 3,17 |
| GEODE CAPITAL MANAGEMENT, LLC | 6.139.621 | 5.981.905 | +2,6% | 2.730.054.399 | 2,78 |
| Capital International Investors | 5.126.077 | 4.733.596 | +8,3% | 2.288.942.362 | 2,33 |
| LOOMIS SAYLES & CO L P | 4.003.821 | 4.033.525 | -0,7% | 1.787.866.287 | 1,82 |
| ALLIANCEBERNSTEIN L.P. | 3.910.786 | 4.496.482 | -13,0% | 1.772.993.941 | 1,80 |
| WELLINGTON MANAGEMENT GROUP LLP | 3.212.589 | 3.821.731 | -15,9% | 1.434.549.493 | 1,46 |
| MORGAN STANLEY | 3.188.881 | 3.120.310 | +2,2% | 1.423.964.743 | 1,45 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 3.057.396 | 3.000.778 | +1,9% | 1.365.249.611 | 1,39 |
| BANK OF AMERICA CORP /DE/ | 2.878.183 | 2.937.030 | -2,0% | 1.285.223.702 | 1,31 |
| JENNISON ASSOCIATES LLC | 2.740.059 | 3.249.541 | -15,7% | 1.223.546.148 | 1,24 |
| Clearbridge Investments, LLC | 2.700.975 | 2.860.176 | -5,6% | 1.206.093.269 | 1,23 |
| AMERIPRISE FINANCIAL INC | 2.633.481 | 2.263.732 | +16,3% | 1.175.957.388 | 1,20 |
| NORTHERN TRUST CORP | 2.564.264 | 2.579.457 | -0,6% | 1.145.046.448 | 1,16 |
| Invesco Ltd. | 2.561.057 | 2.152.672 | +19,0% | 1.143.614.420 | 1,16 |
| GOLDMAN SACHS GROUP INC | 2.466.575 | 1.812.218 | +36,1% | 1.101.424.226 | 1,12 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 1.648 | 252,4 | 110.289 |
| 31.12.2025 | ✓ | 1.622 | 243,6 | 107.386 |
| 30.09.2025 | ✓ | 1.510 | 248,4 | 94.346 |
| 30.06.2025 | ✓ | 1.539 | 248,1 | 105.977 |
| 31.03.2025 | ✓ | 1.574 | 253,5 | 115.489 |
| 31.12.2024 | ✓ | 1.507 | 249,2 | 95.618 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| NORGES BANK | 3.176.613 | 1.440.149.270 |
| Winslow Capital Management, LLC | 887.640 | 405.097.722 |
| Life Cycle Investment Partners Ltd | 366.854 | 166.316.929 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 178.365 | 80.863.431 |
| PFA Pension, Forsikringsaktieselskab | 135.188 | 61.340.182 |
| WORLDQUANT MILLENNIUM ADVISORS LLC | 108.002 | 48.963.787 |
| DIADEMA PARTNERS LP | 98.300 | 44.565.288 |
| Eurizon Capital SGR S.p.A. | 77.394 | 35.086.395 |
| Iron Triangle Partners LP | 76.910 | 34.867.918 |
| Zurich Insurance Group Ltd/FI | 48.699 | 22.078.179 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| BlackRock, Inc. | 23.751.989 | 1.498.942 | +6.7 % | 10.768.201.653 |
| VICTORY CAPITAL MANAGEMENT INC | 3.356.766 | 1.109.200 | +49.4 % | 1.521.850.963 |
| Capital Research Global Investors | 17.316.344 | 763.063 | +4.6 % | 7.850.543.946 |
| AMERICAN CENTURY COMPANIES INC | 848.639 | 399.446 | +88.9 % | 384.738.977 |
| BNP PARIBAS FINANCIAL MARKETS | 559.866 | 305.181 | +119.8 % | 268.317.942 |
| MILLENNIUM MANAGEMENT LLC | 487.964 | 266.222 | +120.1 % | 221.223.359 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 293.301 | 257.829 | +726.9 % | 123.154.155 |
| GOLDMAN SACHS GROUP INC | 1.812.218 | 233.960 | +14.8 % | 821.587.288 |
| Hudson Bay Capital Management LP | 264.518 | 219.203 | +483.7 % | 119.921.881 |
| Clearbridge Investments, LLC | 2.860.176 | 214.412 | +8.1 % | 1.296.689.269 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| FMR LLC | 2.212.596 | -1.091.172 | -33.0 % | 1.003.101.845 |
| WELLINGTON MANAGEMENT GROUP LLP | 3.821.731 | -950.311 | -19.9 % | 1.732.619.966 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.278.958 | -764.847 | -25.1 % | 1.033.189 |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 803.773 | -537.697 | -40.1 % | 364.399.701 |
| EDGEWOOD MANAGEMENT LLC | 1.060.075 | -427.467 | -28.7 % | 480.595.602 |
| Capital World Investors | 25.510.182 | -400.405 | -1.5 % | 11.565.309.006 |
| JPMORGAN CHASE & CO | 6.039.481 | -395.297 | -6.1 % | 2.738.059.237 |
| LAZARD ASSET MANAGEMENT LLC | 198.950 | -345.873 | -63.5 % | 90.196.162 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 211.934 | -291.226 | -57.9 % | 96.082.397 |
| Squarepoint Ops LLC | 411.420 | -245.516 | -37.4 % | 186.521.371 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 14.05.2026 | Capital World Investors | Passiv (13G/A) | 10,10 % | 25.695.015 | -1,10 pp | |
| 14.05.2026 | Capital Research Global Investors | Passiv (13G/A) | 8,30 % | 21.139.169 | +1,50 pp | |
| 30.04.2026 | Vanguard Capital Management | Passiv (13G) | 7,49 % | 19.036.076 | Neu | |
| 27.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -8,65 pp | |
| 12.02.2026 | Capital Research Global Investors | Passiv (13G/A) | 6,80 % | 17.319.044 | +1,10 pp | |
| 13.05.2025 | Capital Research Global Investors | Passiv (13G) | 5,70 % | 14.536.344 | Neu | |
| 13.02.2025 | Capital World Investors | Passiv (13G/A) | 11,20 % | 28.739.975 | +1,20 pp | |
| 12.02.2025 | Abigail P. Johnson | Passiv (13G/A) | 3,60 % | 9.220.827 | Neu | |
| 12.02.2025 | FMR LLC | Passiv (13G/A) | 3,60 % | 9.220.827 | Neu | |
| 10.04.2024 | Capital World Investors | Passiv (13G/A) | 10,00 % | 25.902.938 | +1,40 pp | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 8,65 % | 22.281.729 | +0,26 pp | |
| 09.02.2024 | Capital World Investors | Passiv (13G/A) | 8,60 % | 22.080.207 | +3,60 pp | |
| 25.01.2024 | . BlackRock, Inc. | Passiv (13G) | 8,50 % | 21.881.203 | -0,90 pp | |
| 13.02.2023 | Capital World Investors | Passiv (13G) | 5,00 % | 12.939.319 | Neu | |
| 09.02.2023 | The Vanguard Group | Passiv (13G/A) | 8,39 % | 21.546.903 | +0,46 pp | |
| 24.01.2023 | . BlackRock, Inc. | Passiv (13G) | 9,40 % | 24.241.437 | 0,00 pp | |
| 14.02.2022 | T. ROWE PRICE ASSOCIATES, INC. | Passiv (13G/A) | 2,10 % | 5.421.291 | -5,40 pp | |
| 10.02.2022 | The Vanguard Group | Passiv (13G/A) | 7,93 % | 20.155.842 | +0,07 pp | |
| 01.02.2022 | . BlackRock, Inc. | Passiv (13G/A) | 9,40 % | 23.944.931 | +0,10 pp |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 29.01.2026 | David J. Taylor | – | House | Verkauf | $1,001 – $15,000 |
| 07.08.2025 | David J. Taylor | – | House | Kauf | $1,001 – $15,000 |
| 11.06.2025 | Lisa McClain | – | House | Verkauf | $1,001 – $15,000 |
| 12.05.2025 | Jefferson Shreve | – | House | Verkauf | $15,001 – $50,000 |
| 20.03.2025 | Byron Donalds | – | House | Verkauf | $1,001 – $15,000 |
| 20.03.2025 | Byron Donalds | – | House | Verkauf | $1,001 – $15,000 |
| 13.03.2025 | Jefferson Shreve | – | House | Kauf | $15,001 – $50,000 |
| 24.02.2025 | Jefferson Shreve | – | House | Kauf | $15,001 – $50,000 |
| 11.12.2024 | Lisa McClain | – | House | Kauf | $1,001 – $15,000 |
| 23.10.2024 | Julia Letlow | – | House | Kauf | $1,001 – $15,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Stammdaten
Vertex Pharmaceuticals Incorporated, ein Biotechnologieunternehmen, ist in der Entwicklung und Vermarktung von Therapien zur Behandlung von Mukoviszidose tätig. Das Unternehmen vermarktet SYMDEKO/SYMKEVI, ORKAMBI und KALYDECO zur Behandlung von Patienten mit Mukoviszidose, die spezifische Mutationen im Gen des Cystic Fibrosis Transmembrane Conductance Regulator aufweisen; und TRIKAFTA zur Behandlung von Patienten mit CF ab 6 Jahren, die mindestens eine F508del-Mutation aufweisen. Die Pipeline umfasst VX-864 zur Behandlung von AAT-Mangel, das sich in klinischer Phase 2 befindet; VX-147 zur Behandlung von APOL1-vermittelter fokaler segmentaler Glomerulosklerose oder FSGS und weiterer schwerwiegender Nierenkrankheiten, das sich in klinischer Phase 2 befindet; VX-880, Behandlung von Typ-1-Diabetes, das sich in klinischer Phase 1/2 befindet; VX-548, ein NaV1.8-Inhibitor zur Behandlung akuter, neuropathischer und muskuloskelettaler Schmerzen, das sich in klinischer Phase 2 befindet; und CTX001 zur Behandlung schwerer SCD und TDT, das sich in klinischer Phase 3 befindet. Das Unternehmen verkauft seine Produkte in erster Linie an Spezialapotheken und Spezialgroßhändler in den Vereinigten Staaten sowie an Spezialgroßhändler, Einzelhandelsketten sowie Krankenhäuser und Kliniken international. Das Unternehmen verfügt über Kooperationen mit Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; und Skyhawk Therapeutics, Inc.; sowie Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Deutschland und X-Chem, Inc. Vertex Pharmaceuticals Incorporated wurde 1989 gegründet und hat seinen Hauptsitz in Boston, Massachusetts.
Unternehmen & Branche
| Name | VERTEX PHARMACEUTICALS INC / MA |
|---|---|
| Ticker | VRTX |
| CIK | 0000875320 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 92532F100 |
|---|---|
| ISIN | US92532F1003 |
| Typ | Common Stock |
| Marktkapitalisierung | 110,67 Mrd. USD |
| KGV (P/E) | 28,44 |
| Beta | 0,29 |
Bewertung
| KBV (P/B) | 5,93 vs. 5,53 (2021) ▲ |
|---|---|
| KUV (P/S) | 9,22 vs. 7,38 (2021) ▲ |
| EV/EBITDA | 24,6 vs. 17,2 (2021) ▲ |
| FCF-Rendite | 2,9 % vs. 4,3 % (2021) ▼ |
| Buyback-Rendite | 1,8 % vs. 2,6 % (2021) ▼ |
Qualität & Bilanz
| Bruttomarge | 86,2 % vs. 88,1 % (2021) ▼ |
|---|---|
| Operative Marge | 34,8 % vs. 36,7 % (2021) ▼ |
| Nettomarge | 32,9 % vs. 30,9 % (2021) ▲ |
| ROIC | 19,1 % vs. 21,2 % (2021) ▼ |
| Nettoverschuldung/EBITDA | -0,7 vs. -2,0 (2021) ▲ |
| Zinsdeckungsgrad | 313,8 |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 5,53 | 5,33 | 5,96 | 6,31 | 6,17 | |
| KUV (P/S) | 7,38 | 8,31 | 10,62 | 9,39 | 9,59 | |
| EV/EBITDA | 17,2 | 14,5 | 23,7 | – | 25,6 | |
| FCF-Rendite | 4,3 % | 5,3 % | 3,2 % | -0,8 % | 2,8 % | |
| Buyback-Rendite | 2,6 % | 0,0 % | 0,4 % | 1,1 % | 1,8 % | |
| Qualität & Bilanz | ||||||
| Bruttomarge | 88,1 % | 87,9 % | 87,2 % | 86,1 % | 86,2 % | |
| Operative Marge | 36,7 % | 48,2 % | 38,8 % | -2,1 % | 34,8 % | |
| Nettomarge | 30,9 % | 37,2 % | 36,7 % | -4,9 % | 32,9 % | |
| ROIC | 21,2 % | 22,4 % | 19,7 % | -2,9 % | 19,1 % | |
| Nettoverschuldung/EBITDA | -2,0 | -2,2 | -2,4 | – | -0,7 | |
| Zinsdeckungsgrad | – | 78,6 | 86,9 | -7,6 | 313,8 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 2.986.900.000 | 1.031.400.000 | 4,02 | 26.484.400.000 | 19.361.900.000 |
| 2025-12-31 | 10-K | 12.001.300.000 | 3.953.200.000 | 15,32 | 25.643.000.000 | 18.665.800.000 |
| 2025-09-30 | 10-Q | 3.076.400.000 | 1.082.900.000 | 4,20 | 24.862.300.000 | 17.318.800.000 |
| 2025-06-30 | 10-Q | 2.964.700.000 | 1.032.900.000 | 3,99 | 24.036.700.000 | 17.175.400.000 |
| 2025-03-31 | 10-Q | 2.770.200.000 | 646.300.000 | 2,49 | 22.880.500.000 | 16.496.300.000 |
| 2024-12-31 | 10-K | 11.020.100.000 | -535.600.000 | -2,08 | 22.533.200.000 | 16.409.600.000 |
| 2024-09-30 | 10-Q | 2.771.900.000 | 1.045.400.000 | 4,01 | 22.240.200.000 | 15.630.900.000 |
| 2024-06-30 | 10-Q | 2.645.600.000 | -3.593.600.000 | -13,92 | 20.132.100.000 | 14.774.700.000 |
| 2024-03-31 | 10-Q | 2.690.600.000 | 1.099.600.000 | 4,21 | 23.917.400.000 | 18.546.600.000 |
| 2023-12-31 | 10-K | 9.869.200.000 | 3.619.600.000 | 13,89 | 22.730.200.000 | 17.580.400.000 |
| 2023-09-30 | 10-Q | 2.483.500.000 | 1.035.300.000 | 3,97 | 21.726.200.000 | 16.512.800.000 |
| 2023-06-30 | 10-Q | 2.493.200.000 | 915.700.000 | 3,52 | 20.349.200.000 | 15.470.200.000 |
| 2023-03-31 | 10-Q | 2.374.800.000 | 699.800.000 | 2,69 | 18.974.200.000 | 14.432.300.000 |
| 2022-12-31 | 10-K | 8.930.700.000 | 3.322.000.000 | 12,82 | 18.150.900.000 | 13.912.700.000 |
| 2022-09-30 | 10-Q | 2.334.300.000 | 930.500.000 | 3,59 | 16.706.400.000 | 13.029.600.000 |
| 2022-06-30 | 10-Q | 2.196.200.000 | 810.500.000 | 3,13 | 15.582.200.000 | 11.933.500.000 |
| 2022-03-31 | 10-Q | 2.097.500.000 | 762.100.000 | 2,96 | 14.256.100.000 | 10.907.000.000 |
| 2021-12-31 | 10-K | 7.574.400.000 | 2.342.100.000 | 9,01 | 13.432.500.000 | 10.100.000.000 |
| 2021-09-30 | 10-Q | 1.984.100.000 | 851.900.000 | 3,28 | 12.618.745.000 | 9.530.800.000 |
| 2021-06-30 | 10-Q | 1.793.400.000 | 67.000.000 | 0,26 | 12.221.686.000 | 9.196.400.000 |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Product | 12,0 Mrd. | – | – | – | 7,6 Mrd. | 49,6 % | Neu | |
| TRIKAFTAKAFTRIO | 10,3 Mrd. | 10,2 Mrd. | 8,9 Mrd. | 7,7 Mrd. | 5,7 Mrd. | 42,7 % | +0,7% | |
| ALYFTREK | 837,8 Mio. | – | – | – | – | 3,5 % | Neu | |
| Manufactured Product Other | 820,1 Mio. | 781,5 Mio. | 924,5 Mio. | 1,2 Mrd. | – | 3,4 % | +4,9% | |
| CASGEVY | 115,8 Mio. | 10,0 Mio. | – | – | – | 0,5 % | +1058,0% | |
| JOURNAVX | 59,6 Mio. | – | – | – | – | 0,2 % | Neu | |
| Collaborativeand Royalty | 30,7 Mio. | – | – | – | 1,0 Mio. | 0,1 % | Neu | |
| ORKAMBI | – | – | – | – | 771,6 Mio. | – | – | |
| Kalydeco | – | – | – | – | 684,2 Mio. | – | – | |
| SYMDEKOSYMKEVI | – | – | – | – | 420,4 Mio. | – | – |
Regionen
| Region | FY 2025 | FY 2024 | FY 2023 | FY 2022 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|
| US | 7,5 Mrd. | 6,7 Mrd. | 6,0 Mrd. | 5,7 Mrd. | 45,9 % | +12,9% | |
| Outsidethe United States | 4,5 Mrd. | 4,3 Mrd. | 3,8 Mrd. | 3,2 Mrd. | 27,1 % | +2,7% | |
| Europe | 3,5 Mrd. | 3,5 Mrd. | 3,1 Mrd. | 2,7 Mrd. | 21,0 % | +0,2% | |
| Other Countries Outsideofthe United Statesand Europe | 992,4 Mio. | 881,3 Mio. | 719,8 Mio. | 525,9 Mio. | 6,0 % | +12,6% |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 05.05.2026 | 3,0 Mrd. USD | 4,02 |
| Q3 2025 | 30.09.2025 | 04.11.2025 | 3,1 Mrd. USD | 4,20 |
| Q2 2025 | 30.06.2025 | 05.08.2025 | 3,0 Mrd. USD | 3,99 |
| Q1 2025 | 31.03.2025 | 05.05.2026 | 2,8 Mrd. USD | 2,49 |
| Q3 2024 | 30.09.2024 | 04.11.2025 | 2,8 Mrd. USD | 4,01 |
| Q2 2024 | 30.06.2024 | 05.08.2025 | 2,6 Mrd. USD | -13,92 |
| Q1 2024 | 31.03.2024 | 06.05.2025 | 2,7 Mrd. USD | 4,21 |
| Q3 2023 | 30.09.2023 | 05.11.2024 | 2,5 Mrd. USD | 3,97 |
| Q2 2023 | 30.06.2023 | 02.08.2024 | 2,5 Mrd. USD | 3,52 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 05.05.2026 | 10-Q | 31.03.2026 | 35 Tage | SEC » |
| 13.02.2026 | 10-K | 31.12.2025 | 44 Tage | SEC » |
| 04.11.2025 | 10-Q | 30.09.2025 | 35 Tage | SEC » |
| 05.08.2025 | 10-Q | 30.06.2025 | 36 Tage | SEC » |
| 06.05.2025 | 10-Q | 31.03.2025 | 36 Tage | SEC » |
| 13.02.2025 | 10-K | 31.12.2024 | 44 Tage | SEC » |
| 05.11.2024 | 10-Q | 30.09.2024 | 36 Tage | SEC » |
| 02.08.2024 | 10-Q | 30.06.2024 | 33 Tage | SEC » |
| 07.05.2024 | 10-Q | 31.03.2024 | 37 Tage | SEC » |
| 15.02.2024 | 10-K | 31.12.2023 | 46 Tage | SEC » |
| 07.11.2023 | 10-Q | 30.09.2023 | 38 Tage | SEC » |
| 02.08.2023 | 10-Q | 30.06.2023 | 33 Tage | SEC » |
| 02.05.2023 | 10-Q | 31.03.2023 | 32 Tage | SEC » |
| 10.02.2023 | 10-K | 31.12.2022 | 41 Tage | SEC » |
| 28.10.2022 | 10-Q | 30.09.2022 | 28 Tage | SEC » |
| 05.08.2022 | 10-Q | 30.06.2022 | 36 Tage | SEC » |
| 06.05.2022 | 10-Q | 31.03.2022 | 36 Tage | SEC » |
| 09.02.2022 | 10-K | 31.12.2021 | 40 Tage | SEC » |
| 03.11.2021 | 10-Q | 30.09.2021 | 34 Tage | SEC » |
| 30.07.2021 | 10-Q | 30.06.2021 | 30 Tage | SEC » |
| 30.04.2021 | 10-Q | 31.03.2021 | 30 Tage | SEC » |
| 11.02.2021 | 10-K | 31.12.2020 | 42 Tage | SEC » |
| 30.10.2020 | 10-Q | 30.09.2020 | 30 Tage | SEC » |
| 31.07.2020 | 10-Q | 30.06.2020 | 31 Tage | SEC » |
Filing-Analyse (10-K / 10-Q)
Narrative-Analyse der letzten Quartals-/Jahresberichte durch Claude (nur Coverage-Gruppen-Mitglieder). Keine Anlageberatung — der qualitative Score dient der Einordnung, nicht als Kaufempfehlung; siehe allgemeiner Hinweis am Seitenende.
| Datum | Form | Stimmung | Guidance | Qualitativ | Zusammenfassung | |
|---|---|---|---|---|---|---|
| 13.02.2026 | 10-K | 0,38 | ↑ | 68,0 | Vertex Pharmaceuticals erzielte 2025 einen Umsatz von 12,0 Mrd. USD (+9 %), getragen von anhaltend starker TRIKAFTA/KAFTRIO-Nachfrage sowie … | |
|
Zusammenfassung: Vertex Pharmaceuticals erzielte 2025 einen Umsatz von 12,0 Mrd. USD (+9 %), getragen von anhaltend starker TRIKAFTA/KAFTRIO-Nachfrage sowie ersten Beiträgen aus den Neuzulassungen ALYFTREK, JOURNAVX und CASGEVY; für 2026 erwartet das Management weiteres Umsatzwachstum. Die Pipeline macht substanzielle Fortschritte – insbesondere povetacicept mit laufendem BLA-Rolling-Submission für IgAN und suzetrigine in zwei Phase-3-Studien – und die Liquidität ist mit 12,3 Mrd. USD komfortabel. Belastend wirken eine 379-Mio.-USD-Wertberichtigung auf das eingestellte T1D-Programm VX-264, ein Schiedsverfahren von Royalty Pharma über den ALYFTREK-Royalty-Satz (~8 % vs. Vertex-Position 4 %), ein vorübergehender Dosierstopp beim zimislecel-T1D-Programm sowie das FDA-Signal, dass eine breite neuropathische Schmerzindikation für suzetrigine zum jetzigen Zeitpunkt nicht absehbar ist. Die hohe CF-Umsatzkonzentration und zunehmende Preis- und Erstattungsrisiken bleiben strukturelle Risikofaktoren. Guidance-Zitate:
Red Flags:
|
||||||
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (13.05.2026)
HOCH Abgang Schlüsselpersonen (29.04.2026)
HOCH Abgang Schlüsselpersonen (13.05.2026)
HOCH Abgang Schlüsselpersonen (29.04.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 13.05.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors of Directors or Certain Officers; Election of Directors; Appointment of Certain… |
| 29.04.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 05.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors… |
| 05.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors… |
| 01.04.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-05-07 | 1 | 427,65 | 428 |
| 2026-05-06 | 214 | 424,36 | 90.813 |
| 2026-05-04 | 14 | 423,92 | 5.935 |
| 2026-04-24 | 1.290 | 435,10 | 561.279 |
| 2026-04-23 | 1 | 437,67 | 438 |
| 2026-04-16 | 2.143 | 441,70 | 946.563 |
| 2026-04-15 | 14 | 444,28 | 6.220 |
| 2026-04-08 | 1 | 431,86 | 432 |
| 2026-03-30 | 42.186 | 433,07 | 18.269.491 |
| 2026-03-25 | 5.705 | 448,62 | 2.559.377 |
| 2026-03-23 | 2.095 | 454,00 | 951.130 |
| 2026-03-17 | 40.515 | 466,10 | 18.884.042 |
| 2026-03-13 | 341 | 478,13 | 163.042 |
| 2026-02-25 | 300 | 487,43 | 146.229 |
| 2026-02-24 | 300 | 481,01 | 144.303 |
| 2026-02-20 | 1.216 | 469,27 | 570.632 |
| 2026-02-18 | 72 | 477,32 | 34.367 |
| 2026-02-17 | 14.013 | 491,47 | 6.886.969 |
| 2026-02-13 | 300 | 465,02 | 139.506 |
| 2026-02-12 | 3.833 | 461,24 | 1.767.933 |
| 2026-02-09 | 2.800 | 477,92 | 1.338.176 |
| 2026-02-04 | 915 | 465,61 | 426.033 |
| 2026-02-02 | 200 | 469,90 | 93.980 |
| 2026-01-16 | 134 | 438,92 | 58.815 |
| 2026-01-13 | 1 | 460,59 | 461 |
| 2026-01-09 | 18 | 469,68 | 8.454 |
| 2026-01-06 | 136 | 448,80 | 61.037 |
| 2026-01-05 | 791 | 452,13 | 357.635 |
| 2025-12-31 | 10 | 453,74 | 4.537 |
| 2025-12-29 | 1.000 | 462,90 | 462.900 |
| 2025-12-18 | 66 | 449,52 | 29.668 |
| 2025-12-17 | 14.014 | 454,96 | 6.375.809 |